Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Luca BenattiDirector | Quince TherapeuticsQNCX | Open-market sale | 25/12/26 | 25/12/29 | 50,000 sh | $3.47 | $173,500 | −56.1% |
Quince TherapeuticsQNCX | Open-market buy | 24/08/29–24/08/30 | 24/09/03 | 154,500 sh2 trades | $0.69avg. | $107,375 | +22.4% | |
Charles S. RyanPresident | Quince TherapeuticsQNCX | Open-market buy | 24/08/20 | 24/08/22 | 48,387 sh | $0.65 | $31,451.55 | +65.3% |
Quince TherapeuticsQNCX | Open-market buy | 24/08/19–24/08/21 | 24/08/21 | 38,924 sh6 trades | $0.62avg. | $24,166.05 | +15.1% | |
Quince TherapeuticsQNCX | Open-market buy | 23/12/12–23/12/14 | 23/12/14 | 67,881 sh4 trades | $1.02avg. | $69,232.62 | No record | |
Quince TherapeuticsQNCX | Open-market buy | 23/12/05–23/12/07 | 23/12/07 | 57,369 sh3 trades | $1.01avg. | $58,133.92 | +2.6% | |
Quince TherapeuticsQNCX | Open-market buy | 23/11/29–23/12/01 | 23/12/01 | 43,134 sh3 trades | $0.94avg. | $40,545.96 | +2.0% | |
Quince TherapeuticsQNCX | Open-market buy | 23/08/30–23/08/31 | 23/08/31 | 82,052 sh2 trades | $1.32avg. | $107,898.38 | +3.9% | |
Quince TherapeuticsQNCX | Open-market buy | 23/08/15–23/08/17 | 23/08/17 | 250,000 sh3 trades | $1.30avg. | $325,736.58 | +13.5% | |
Dirk ThyeCEO | Quince TherapeuticsQNCX | Open-market buy | 23/08/10 | 23/08/11 | 88,000 sh | $1.26 | $110,880 | +24.4% |
Dirk ThyeCEO | Quince TherapeuticsQNCX | Open-market buy | 23/08/08 | 23/08/09 | 80,000 sh | $1.24 | $99,200 | +28.5% |
Margaret McLoughlinDirector | Quince TherapeuticsQNCX | Open-market buy | 23/08/08 | 23/08/09 | 8,000 sh | $1.23 | $9,840 | No record |
Brendan HannahChief Business Officer | Quince TherapeuticsQNCX | Open-market buy | 23/08/08 | 23/08/09 | 71,762 sh | $1.22 | $87,549.64 | +55.3% |
Ted MonohonChief Accounting Officer & VP | Quince TherapeuticsQNCX | Open-market sale | 23/03/06 | 23/03/06 | 1,871 sh | $0.98 | $1,833.58 | −6.4% |